Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
green tea and quercetin+ docetaxel · 1 trial · 1 indication
Blood PSA will be measured at baseline, 1st day of each cycle of docetaxel treatment (21 days per cycle, for 3 cycles), and at the end of the intervention.
| Arm | Type | Description |
|---|---|---|
| green tea and quercetin | EXPERIMENTAL | Green tea and quercetin capsules will be administered in combination with docetaxel treatment. |
| placebo | PLACEBO_COMPARATOR | Placebo capsules will be administered in combination with docetaxel treatment as comparison. |
| Name | Type | Description |
|---|---|---|
| green tea and quercetin + docetaxel | DRUG | green tea and quercetin supplements in combination with docetaxel infusion |
| Placebo + docetaxel | DRUG | Placebo will be given along with docetaxel chemotherapy |
Inclusion Criteria: * Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization. * Stated willingness to comply with all study procedures and availability for the duration of the study. * Male patients 18 years or older * Diagnosed with met...
Green tea and quercetin + docetaxel is an investigational combination being studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It combines green tea and quercetin with the chemotherapy drug docetaxel. The therapy is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Green tea and quercetin + docetaxel is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting a Phase 1 clinical trial to evaluate this combination therapy in patients with metastatic castration-resistant prostate cancer.
Green tea and quercetin + docetaxel is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is actively recruiting patients with metastatic castration-resistant prostate cancer.
Green tea and quercetin + docetaxel is being evaluated in a single Phase 1 clinical trial, NCT06615752, titled 'Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients.' The trial is recruiting in the United States and aims to enroll 99 male patients aged 18 years and older.
Yes, green tea and quercetin + docetaxel is also known as green tea and quercetin + docetaxel. These names refer to the same investigational combination therapy being developed by National Healthcare Corp. for metastatic castration-resistant prostate cancer.